Brazilian study maps HER2 in Women's cancers to guide future treatments
NCT ID NCT07101081
First seen Jun 25, 2026 · Last updated Jun 30, 2026 · Updated 3 times
Summary
This study will test tumor samples from 350 adults with gynecological cancers (endometrial, ovarian, cervical, vulvar, and vaginal) to see how often they have high levels of the HER2 protein. Researchers will use two standard lab tests to measure HER2. The goal is to learn how common HER2-high cancers are in Brazil, which could help doctors decide who might benefit from HER2-targeted drugs in the future.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this study could help identify which patients with gynecological cancers might benefit from HER2-targeted therapies in the future.
What could go wrong
This is an observational study, not a treatment trial. It only measures HER2 levels and does not test any drug, so it cannot directly improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
RECRUITINGSão Paulo, Brazil